Fecal Pyruvate Kinase-M2 (Tumor M2-PK) Measurement: A New Screening Concept for Colorectal Cancer

Background: Colorectal cancer (CRC) is a disease with major impact on public health and public health costs. Colonoscopy is purportedly the best screening tool for CRC. However, the acceptance by the general population is very poor. Therefore evaluation of additional screening tools is of great inte...

Full description

Saved in:
Bibliographic Details
Published inAnticancer research Vol. 27; no. 4A; pp. 1949 - 1952
Main Authors EWALD, Nils, SCHALLER, Markus, BAYER, Martin, AKINCI, Ahmet, BRETZEL, Reinhard G, KLOER, Hans-Ulrich, HARDT, Philip D
Format Journal Article Conference Proceeding
LanguageEnglish
Published Attiki International Institute of Anticancer Research 01.07.2007
Subjects
Aged
Biological and medical sciences
Biomarkers, Tumor - analysis
Colorectal Neoplasms - diagnosis
Feces - chemistry
Gastroenterology. Liver. Pancreas. Abdomen
Humans
Mass Screening - methods
Medical sciences
Middle Aged
Pyruvate Kinase - analysis
Sensitivity and Specificity
Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
Tumors
stool
Rectal disease
Pyruvate kinase
Enzyme
Tumor M2-PK
Transferases
Colorectal cancer
Malignant tumor
Medical screening
Colonic disease
tumor screening
Cancerology
Digestive diseases
Intestinal disease
Feces
Online AccessGet full text

Cover

More Information
Summary:Background: Colorectal cancer (CRC) is a disease with major impact on public health and public health costs. Colonoscopy is purportedly the best screening tool for CRC. However, the acceptance by the general population is very poor. Therefore evaluation of additional screening tools is of great interest. Patients and Methods: The use of M2-PK measurement in the feces has been reported in 6 studies to date. The data of these studies were analysed and critically reviewed. Additionally, 1,906 persons undergoing routine health care check-up provided stool samples for M2-PK measurement. Results: The overall sensitivity of M2-PK is 77.9% for CRC. Specificity ranges from 74.3 to 83.3%. Of the 1,906 screened persons, 90.4% had results within the normal range, while 9.6% had elevated results. Conclusion: Measurement of tumor M2-PK in feces seems to be the most promising tool for CRC screening at the present time. In combination with colonoscopy, this test should hence be recommended for CRC screening programs.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0250-7005
1791-7530